on the FDA side, this is enlightening: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538397/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538397/ "Each drug

on the FDA side, this is enlightening: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538397/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538397/ "Each drug is estimated to cost $1.2 billion to $1.3 billion in cash outlays per approved biopharmaceutical" This particular problem means that lots of very promising cancer drugs never see the light of day. For example for Neuroblastoma there is an approved drug called dinutuximab https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=42042 https://www.cancer.gov/publications/dictionaries/cancer-drug.... This is the only approved drug for treating pediatric cancers that was approved in the last 10-20 year. Meantime significantly more potent (and possibly effective) drugs are in clinical trials, eg: Hu-3F8 at MSKCC. But... given the cost and enormous amount of red tape needed to get the drug approved (combined with very small market) odds of them getting approved in the next 10 years are not that high. Something needs to change, but I am not sure exactly what.